Webcasts

Exelixis Announces Webcast of Investor Conference Presentations in December


ALAMEDA, Calif .– (COMMERCIAL THREAD) – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the Exelixis leadership team will provide an overview of the company at the following investor conferences in December:

  • Evercore ISI 2sd The annual HealthCONx: Exelixis conference is scheduled for 8:45 a.m. EST / 5:45 a.m. PST on Tuesday, December 3, 2019 in Boston.

  • Piper jaffray 31st Annual Healthcare Conference: Exelixis is scheduled to present at 10:00 a.m. EST / 7:00 a.m. PST on Tuesday, December 3, 2019 in New York City.

To access the webcast links, log in www.exelixis.com and go to the News & Events / Calendar of Events page under Investors & Media. Please log into the company’s website at least 15 minutes prior to the presentation to ensure sufficient time for any software downloads that may be required to listen to the webcasts. Replays will also be available in the same location for 14 days.

About Exelixis

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful oncology-focused biotechnology company working to accelerate the discovery, development and commercialization of new drugs for difficult-to-treat cancers. . Following the early work on the genetics of model systems, we established an extensive drug discovery and development platform that has served as the basis for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we’ve partnered with leading pharmaceutical companies to bring these important drugs to patients around the world. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business in order to maximize the potential of our pipeline. We complement our existing therapeutic assets with targeted business development and in-house drug discovery activities, all to deliver the next generation of Exelixis drugs and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 Index, which measures the performance of profitable mid-sized companies. For more information on Exelixis, please visit www.exelixis.com, to follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.

Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks in the United States. MINNEBRO is a Japanese registered trademark.